SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 1

Hepatitis A susceptibility parallels high COVID-19 mortality

Fatma Burcu BELEN
Kadir Mutlu HAYRAN
Faik SARIALİOĞLU
Pages
382–384
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: When the data from 213 countries were analyzed, it was found that there was a significant increasing trend in COVID-19 mortality rates by HAV susceptibility (P

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim:COVID-19 has become the biggest health problem of this century.
📊
Key Findings & Data:It has been hypothesized that immunity against hepatitis A virus (HAV) may provide protection from COVID- 19.
💡
Conclusion & Impact:Results: When the data from 213 countries were analyzed, it was found that there was a significant increasing trend in COVID-19 mortality rates by HAV susceptibility (P
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Abstract

Background/aim:COVID-19 has become the biggest health problem of this century. It has been hypothesized that immunity against hepatitis A virus (HAV) may provide protection from COVID- 19. Materials and methods: As of 10June 2020, the infection had spread to 213 countries, with 7.3 million people infected and 413,733 dead. This data was combined with the World Health Organization susceptibility classification on the worldwide prevalence of HAV, and the relationship between HAV susceptibility and COVID-19 mortality were analyzed. Results: When the data from 213 countries were analyzed, it was found that there was a significant increasing trend in COVID-19 mortality rates by HAV susceptibility (P

🔖

Cite This Article

BELEN, F. B., HAYRAN, K. M., SARIALİOĞLU, F. (2022). Hepatitis A susceptibility parallels high COVID-19 mortality. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 1, 382–384. https://ajindex.com/articles/609331

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Sarialioglu F, Belen Apak FB, Haberal M. Can hepatitis A vaccine provide protection against COVID-19? Experimental and Clinical Transplantation 2020; 18 (2): 141‐143. doi: 10.6002/ect.2020.0109 2. Jacobsen KH. The global prevalence of hepatitis A virus infection and susceptibility: a systematic review. Report number: WHO/IVB/10.01. Geneva, Switzerland: World Health Organization; 2009. 3. Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki SI et al. Natural history of asymptomatic SARS-CoV-2 infection. The New England Journal of Medicine 2020; 383: 885-886. doi: 10.1056/NEJMc2013020 4. Nelson NP. Travel related infectious diseases- hepatitis A. In: Brunette GW, Nemhauser JB (editors). Centers for Disease Control and Prevention. CDC Yellow Book 2020: Health Information for International Travel. New York, NY, USA: Oxford University Press; 2017.